Gainers
- Spruce Biosciences SPRB stock rose 80.0% to $2.25 during Friday's pre-market session. The market value of their outstanding shares is at $53.0 million.
- CytomX Therapeutics CTMX stock moved upwards by 62.01% to $2.9. The market value of their outstanding shares is at $191.6 million.
- Scilex Holding SCLX shares rose 20.43% to $6.01. The market value of their outstanding shares is at $849.4 million.
- Gelesis Holdings GLS shares rose 19.38% to $0.46. The market value of their outstanding shares is at $33.5 million.
- Immix Biopharma IMMX shares moved upwards by 19.21% to $3.04. The market value of their outstanding shares is at $42.3 million.
- Talkspace TALK stock rose 18.15% to $0.69. The company's market cap stands at $109.8 million.
Losers
- Fate Therapeutics FATE stock declined by 52.0% to $5.28 during Friday's pre-market session. The company's market cap stands at $513.0 million.
- Graphite Bio GRPH shares decreased by 49.68% to $1.54. The company's market cap stands at $89.5 million.
- Eloxx Pharmaceuticals ELOX stock declined by 20.61% to $3.43. The company's market cap stands at $7.4 million.
- Vyant Bio VYNT shares fell 17.36% to $1.0. The company's market cap stands at $5.9 million.
- ABVC BioPharma ABVC shares decreased by 16.73% to $0.89. The company's market cap stands at $29.0 million.
- Bellerophon Therapeutics BLPH shares fell 14.42% to $1.96. The company's market cap stands at $18.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
ABVCABVC BioPharma Inc
$2.98-1.34%
Edge Rankings
Momentum
99.18
Growth
N/A
Quality
N/A
Value
6.60
Price Trend
Short
Medium
Long
BLPHBellerophon Therapeutics Inc Com (New)
$0.0120-88.3%
CTMXCytomX Therapeutics Inc
$2.24-6.28%
ELOXEloxx Pharmaceuticals Inc
$0.00010-100.0%
IMMXImmix Biopharma Inc
$2.71-0.37%
SCLXScilex Holding Co
$16.868.63%
SPRBSpruce Biosciences Inc
$0.108037.4%
TALKTalkspace Inc
$2.601.56%
FATEFate Therapeutics Inc
$1.19-8.85%
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.